References
- Siegal R, Jemal A. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society, 2014
- Ettinger DS, Wood DE, Loo BW, et al. NCCN clinical practices in oncology: non-small cell lung cancer (Version 6.2015). Ft. Washington, PA: National Comprehensive Cancer Network, 2015
- Sandler A, Gray R, Perry MC, et al. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
- Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
- Scagliotti G1, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:64-70
- Novello S, Pimentel FL, Douillard JY, et al. Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:1602-8
- Surveillance, Epidemiology, and End Results Program (SEER). SEER stat fact sheets: lung and bronchus cancer. 2014. http://seer.cancer.gov/statfacts/html/lungb.html. Accessed February 2, 2015
- Levit LA, Balogh EP, Nass SJ, Ganz PA, eds. Institute of Medicine (IOM). Delivering high-quality cancer care: charting a new course for a system in crisis. 2013. http://www.nationalacademies.org/hmd/Reports/2013/Delivering-High-Quality-Cancer-Care-Charting-a-New-Course-for-a-System-in-Crisis.aspx. Accessed March 13, 2015
- Davis KL, Goyal RK, Able SL, et al. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Lung Cancer 2015;87:176-85
- Langer C, Ravelo A, Hazard SJ, et al. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. Lung Cancer 2014;86:350-7
- Lamont EB, Schilsky RL, He Y, et al. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst 2015;107:336
- Owonikoko TK, Ragin C, Chen Z, et al. Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER–Medicare analysis. Oncologist 2013;18:600-10
- Moro-Sibilot D, Smit E, de Castro Carpeño J, et al. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer 2015;88:215-22
- Shah M, Winfree KB, Peterson P, et al. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. Lung Cancer 2013;82:121-7
- American Society of Clinical Oncology (ASCO). Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-9
- Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009;27:3868-74
- National Cancer Institute. FDA Approval for Pemetrexed Disodium. Bethesda, MD: National Cancer Institute, 2013. http://www.cancer.gov/cancertopics/druginfo/fda-pemetrexed-disodium. Accessed December 19, 2014
- Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17:584-90
- Zhu J, Sharma DB, Gray SW, et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 2012;307:1593-601
- Zhu J, Sharma DB, Chen AB, et al. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. Cancer 2013;119:2048-60
- Lin DY, Feuer EJ, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-34
- Obenchain RL. Resampling and multiplicity in cost-effectiveness inference. J Biopharm Stat 1999;9:563-82
- Neumann PJ, Cohen JT, Weinstein M. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-7